Download PDF
Arzneimittelforschung 2010; 60(6): 324-329
DOI: 10.1055/s-0031-1296295
Immunomodulators · Immunostimulants · Immunosuppressants
Editio Cantor Verlag Aulendorf (Germany)

Immunostimulatory properties of the bacterial extract OM-89 in vitro and in vivo

Wolfgang G. Bessler
1   Institute for Molecular Medicine and Cell Research, University Clinic, Freiburg, Germany
,
Ulrichvordem Esche
1   Institute for Molecular Medicine and Cell Research, University Clinic, Freiburg, Germany
,
Andrea Zgaga-Griesz
1   Institute for Molecular Medicine and Cell Research, University Clinic, Freiburg, Germany
,
Ravshan Ataullakhanov
2   Institute for Immunology, Moscow, Russian Federation
› Author Affiliations
Further Information

Publication History

Publication Date:
02 December 2011 (online)

    Permissions and Reprints

Abstract

The therapeutic agent OM-89 (Uro-Vaxom®) contains lyophilized immunostimulating fractions from 18 Escherichia coli strains. It has been shown to provide protection against recurrent urinary tract infections in humans and against bacterial infections in mice. Here the immuno-stimulatory properties of OM-89 were investigated by in vitro and in vivo assays. in vitro the activation of murine spleen cells by the AlamarBlueTM assay was determined. OM-89 was effective in stimulating the metabolism of spleen cells within a concentration range of 0.625 -2.5 mg/ml. The activation of murine bone marrow-derived macrophages by OM-89 was shown by the induction of NO production; OM-89 was a most effective stimulant at concentrations around 6 mg/ml. In the human system, the effect of OM-89 was tested in vitro: the metabolic activity of peripheral blood lymphocytes (PBL) was stimulated starting at concentrations of approx. 250 μg/ml, and the spontaneous apoptosis of polymorphonuclear neutrophils (PMN) was reduced starting at OM-89 concentrations of approx. 100 μg/ml. Finally, in a mouse model, the in vivo protection of mice against infection with Salmonella typhimurium after the oral administration of OM-89 was tested (100 mg in a volume of 0.5 ml once a day for 10 consecutive days). The extract proved to be effective: 90 % of the OM-89-treated animals survived compared to 58 % of the untreated control group.

Key words

Bacterial extract - Immunostimulation - OM-89 - Urinary tract infections - Uro-Vaxom® - Vaccination
 

  • References

  • 1 Frey C, Obolenski W, Wyss H. Treatment of recurrent urinary tract infections: efficacy of an orally administered biological response modifier. Urol Int. 1986; 41: 444-6
    CrossrefPubMedGoogle Scholar
  • 2 Hachen HJ. Oral immunotherapy in paraplegic patients with chronic urinary tract infections: a double-blind, placebo-controlled trial. J Urol. 1990; 143: 759-63
    PubMedGoogle Scholar
  • 3 Tammen H. Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. Br J Urol. 1990; 65: 6-9
    CrossrefPubMedGoogle Scholar
  • 4 Schulman CC, Corbusier A, Michiels H, Taenzer HJ. Oral immunotherapy of recurrent urinary tract infections: a double-blind placebo-controlled multicenter study. J Urol. 1993; 150: 917-21
    PubMedGoogle Scholar
  • 5 Magasi P, Panovics J, Illes A, Nagy M. Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial. Eur Urol. 1994; 26: 137-40
    PubMedGoogle Scholar
  • 6 Bauer HW, Alloussi S, Egger G, Blumlein HM, Cozma G, Schulman CC on behalf of Multicenter UTI Study Group A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol. 2005; 47 (4) 542-8
    CrossrefPubMedGoogle Scholar
  • 7 Bosch A, Benedi KJ, Pares R. Enhancement of the humoral immune response and resistance to bacterial infection in mice by the oral administration of a bacterial immunomodulator (OM-89). Immunopharmacol Immunotoxicol. 1988; 10: 333-43
    CrossrefPubMedGoogle Scholar
  • 8 Wybran J, Libin M, Schandene L. Enhancement of cytokine production and natural killer activity by an Escherichia coli extract. Immunopharmacol Immunotoxicol. 1989; 11: 17-32
    CrossrefPubMedGoogle Scholar
  • 9 Bessler WG, Beck P, Konetznick U, Loleit M, Sedelmeier E, Hoffmann P et al Biological activity of bacterial surface components: immunogenicity and immunomodulatory properties of a bacterial extract from Escherichia coli. Arzneimittelforschung. 1991; 41 (3) 274-9
    PubMedGoogle Scholar
  • 10 Huber M, Ayoub M, Pfannes S, Mittenbühler K, Weis K, Eckert M et al Immunostimulatory activity of the bacterial extract OM-89. Eur J Med Res. 2000; 5: 101-9
    PubMedGoogle Scholar
  • 11 Bessler WG, Kleine B, Martinez A, Biesert L, Strecker M, Wiesmüller K et al Biological activity of bacterial surface components: bacterial extracts and defined bacterial cell wall components as immunmodulators. Lung. 1990; 168: 707-15
    CrossrefPubMedGoogle Scholar
  • 12 Sedelmeier E, Bessler WG. Biological activity of bacterial cell wall components: immunogenicity of the bacterial extract OM-89. Immunopharmacology. 1995; 29: 29-36
    CrossrefPubMedGoogle Scholar
  • 13 Huber M, Baier W, Serr A, Bessler WG. Immunogenicity of an E. coli extract after oral or intraperitoneal administration: Induction of antibodies against pathogenic bacterial strains. Int J Immunopharmacol. 2000; 22: 57-68
    CrossrefPubMedGoogle Scholar
  • 14 Baier W, Sedelmeier E, Bessler WG. Studies on the immunogenicity of an Escherichia coli extract after oral application in mice. Arzneimittelforschung. 1997; 47 (8) 980-5
    PubMedGoogle Scholar
  • 15 Huber M, Krauter K, Winkelmann G, Bauer HW, Rahlfs VW, Lauener PA et al Immunostimulation by bacterial components: II. Efficacy studies and meta-analysis of the bacterial extract OM-89. Int J Immunopharmacol. 2000; 22: 1103-11
    CrossrefPubMedGoogle Scholar
  • 16 Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J Immunol. 1988; 141: 2407-12
    PubMedGoogle Scholar
  • 17 Hoffmann P, Wiesmüller KH, Metzger J, Jung G, Bessler WG. Induction of tumor cytotoxicity in murine bone marrow derived macrophages by two synthetic lipopeptide analogues. Biol Chem Hoppe Seyler. 1989; 370: 575-82
    CrossrefPubMedGoogle Scholar
  • 18 Meng G, Grabiec A, Vallon M, Ebe B, Hampel S, Bessler W et al Cellular recognition of tri-/di-palmitoylated peptides is independent from a domain encompassing the N-terminal seven leucine-rich repeat (LRR)/LRR-like motifs of TLR2. J Biol Chem. 2003; 278: 39822-9
    CrossrefPubMedGoogle Scholar
  • 19 Triantafilou M, Triantafilou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol. 2002; 23 (6) 301-4
    CrossrefPubMedGoogle Scholar
  • 20 Bessler WG, Puce K, vordemEsche U, Kirschning C, Huber M. Immunomodulating effects of OM-89, a bacterial extract from Escherichia coli, in murine and human leukocytes. Arzneimittelforschung. 2009; 59 (11) 571-7
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Schmidhammer S, Ramoner R, Holtl L, Bartsch G, Thurner M, Zelle-Rieser C. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology. 2002; 60 (3) 521-6
    CrossrefPubMedGoogle Scholar
  • 22 Mauer AM, Athens JW, Ashenbrucker H, Cartwright GE, Wintrobe MM. Leukokinetic studies: a method for labeling granulocytes in vitro with radioactive diisopropylfluoro-phosphate (Dfp). J Clin Invest. 1960; 39: 1481-6
    CrossrefPubMedGoogle Scholar
  • 23 Coxon A, Tang T, Mayadas TN. Cytokine-activated endothelial cells delay neutrophil apoptosis in vitro and in vivo: a role for granulocyte/macrophage colony-stimulating factor. J Exp Med. 1999; 190: 923-34
    CrossrefPubMedGoogle Scholar
  • 24 Watson RW, Rotstein OD, Nathens AB, Parodo J, Marshall JC. Neutrophil apoptosis is modulated by endothelial transmigration and adhesion molecule engagement. J Immunol. 1997; 158: 945-53
    PubMedGoogle Scholar